Testosterone Solution Found Safe, Effective for Hypogonadal Men

This article originally appeared here.
Share this content:
Testosterone Solution Found Safe, Effective for Hypogonadal Men
Testosterone Solution Found Safe, Effective for Hypogonadal Men

MONDAY, Aug. 22, 2016 (HealthDay News) -- Once-daily 2 percent testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men, according to a study published online in The Journal of Urology.

Gerald Brock, M.D., from the University of Western Ontario in London, Canada, and colleagues examined the continued safety and efficacy of T-sol in a six-month open-label extension study following a three-month placebo controlled study. Five hundred fifty-eight hypogonadal participants (mean age, 55 years) were enrolled in the open-label study. Of these, 275 and 283 had previously received placebo and T-sol, respectively, in the double-blind phase.

The researchers found that 60 and 66 percent of the participants in the formerly placebo and continuing active treatment groups, respectively, had total testosterone levels within the normal range at the completion of the open-label phase. During the open-label phase, there were baseline to end point improvements for both groups in the Sexual Arousal, Interest, and Drive score (both P < 0.001) and Hypogonadism Energy Diary score (both P < 0.001). There were no reports of new safety concerns.

"Once-daily T-sol administered for six months in an open-label study did not indicate new safety concerns, and the outcomes of low sex drive and low energy showed further improvement after the double-blind phase," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which assisted with trial administration.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »